- Home
- TERN
as 04-01-2025 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 298.1M | IPO Year: | 2021 |
| Target Price: | $18.30 | AVG Volume (30 days): | 983.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.56 - $11.40 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burroughs Amy L. | TERN | Chief Executive Officer | Jan 30 '25 | Buy | $5.11 | 510 | $2,606.10 | 19,609 | |
| Jung Melita Sun | TERN | Chief Business Officer | Jan 30 '25 | Buy | $5.11 | 2,250 | $11,497.50 | 2,250 | |
| Quigley Jill M. | TERN | Director | Jan 2 '25 | Sell | $5.72 | 6,240 | $35,702.16 | 8,760 | |
| Vignola Mark J. | TERN | Chief Financial Officer | Jan 2 '25 | Sell | $5.76 | 17,188 | $99,023.52 | 83,811 | |
| Kuriakose Emil | TERN | Chief Medical Officer | Jan 2 '25 | Sell | $5.71 | 4,481 | $25,607.12 | 54,269 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
GlobeNewswire
13 days ago
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Motley Fool
24 days ago
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
MT Newswires
a month ago
William Blair Initiates Terns Pharmaceuticals at Market Perform
GlobeNewswire
a month ago
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
a month ago
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
MT Newswires
a month ago
Terns Pharmaceuticals Names Andrew Gengos as Chief Financial Officer
Pharma Voice
a month ago
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.